Market Overview

UPDATE: Credit Suisse Initiates Outperform, $7 PT on XenoPort; Valuation Trumps Fundamental Concerns

Related XNPT
XenoPort's XP23829 in Phase II Study - Analyst Blog
Xenoport, Inc. (XNPT) Soars: Stock Up 5.9% - Tale of the Tape

Credit Suisse initiates its coverage on XenoPort (NASDAQ: XNPT) with an Outperform rating and a price target of $7 per share.

Credit Suisse says, "Despite a number of fundamental concerns, at its current valuation ($219mn market cap/$165mn y/e EV) and with low expectations for its marketed products and pipeline, we think relatively little has to go right for the stock price to appreciate. Specifically we see 3 main upside optionality triggers which are not factored into our numbers/valuation (a) delivery of greater Regnite/Horizant revenues - either via high end-user sales and/or US re-partnering (b) monetization of clinical assets, in particular XP23829 or (c) the company seeks strategic alternatives."

XNPT closed at $6.07 on Wednesday.

Latest Ratings for XNPT

DateFirmActionFromTo
Apr 2014JefferiesInitiates Coverage onBuy
Jun 2013Morgan StanleyDowngradesEqual-weightUnderweight
May 2013Deutsche BankMaintainsBuyBuy

View More Analyst Ratings for XNPT
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (XNPT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters